Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)

NCT00811967 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic
Liver Cirrhosis

Interventions

BIOLOGICAL: PegIntron (peginterferon alfa-2b; SCH 54031)
DRUG: Rebetol (ribavirin; SCH 18908)

Sponsor

Merck Sharp & Dohme LLC